ATNMActinium Pharmaceuticals, Inc.同业对比
Actinium Pharmaceuticals, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATNM本股 | $40M#7 | 3.6x#2 | 1.3x#7 | 443.7x#8 | — | 11.4%#5 | -40274.4%#8 | -111.8%#5 | — | — | -22.8%#1 | — |
| ELTX | $47M#1 | — | 5.9x#10 | 20.2x#6 | -91.9%#6 | 23.8%#3 | -1639.0%#6 | -498.6%#10 | — | — | -84.3%#7 | — |
| HOWL | $46M#2 | — | 2.8x#9 | — | — | 13.7%#4 | — | -373.3%#8 | -229.9%#3 | — | -34.6%#2 | — |
| ANVS | $46M#3 | — | — | — | — | -17.3%#6 | — | — | — | — | — | — |
| MCRB | $42M#4 | — | 1.2x#6 | 53.4x#7 | — | 4088.2%#1 | -11910.1%#7 | 16.5%#1 | -72.9%#2 | — | -75.4%#6 | — |
| SDEV | $42M#5 | — | 0.3x#1 | 4.3x#4 | -6.4%#4 | -8632.9%#12 | -86.3%#3 | -495.7%#9 | -7.0%#1 | — | -91.5%#8 | 11.6%#1 |
| SCYX | $41M#6 | 14.8x#3 | 0.6x#4 | 2.0x#3 | 449.9%#1 | 59.6%#2 | -78.0%#2 | -12.9%#2 | — | 7#1 | -52.1%#3 | — |
| KPTI | $39M#8 | — | — | 0.3x#1 | 0.6%#3 | -156.5%#9 | -62.1%#1 | — | — | — | -72.2%#5 | — |
| CRVO | $37M#9 | 0.0x#1 | 1.6x#8 | 9.2x#5 | -58.9%#5 | -65.6%#8 | -706.2%#5 | -117.5%#6 | -5165.9%#4 | — | — | — |
| CNTX | $34M#10 | — | 0.9x#5 | — | — | -35.2%#7 | — | -94.6%#4 | — | — | — | — |
| LITS | $34M#11 | — | 0.6x#3 | — | -100.0%#7 | -189.7%#10 | — | -28.1%#3 | — | — | -62.4%#4 | — |
| FLNA | $33M#12 | — | 0.5x#2 | 0.8x#2 | 277.6%#2 | -273.7%#11 | -232.0%#4 | -133.5%#7 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议